Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-1303 in moderate to severe active Crohn's disease
NCT02378688Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Mar 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of amiselimod in Crohn's disease, sponsored by Mitsubishi Tanabe Pharma Corporation. Started Mar 2015; status: completed.
02
Drugs
amiselimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02378688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378688.